Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.50 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10772299 | 0.85 | KMT2A (0.70) | KMT2AMEN1MAPTLMNANPSR1 | |
| SCHEMBL11812896 | 0.85 | KMT2A (0.70) | KMT2AMEN1MAPTLMNANPSR1 | |
| SCHEMBL11823592 | 0.83 | KMT2A (0.66) | KMT2AMEN1MAPTLMNANPSR1 | |
| SCHEMBL18131546 | 0.83 | KMT2A (0.66) | KMT2AMEN1MAPTLMNANPSR1 | |
| SCHEMBL11810976 | 0.81 | MEN1 (0.64) | KMT2AMEN1MAPTLMNANPSR1 | |
| SCHEMBL31483413 | 0.81 | KMT2A (0.64) | KMT2AMEN1MAPTLMNANPSR1 | |
| SCHEMBL31488000 | 0.81 | MEN1 (0.64) | KMT2AMEN1MAPTLMNANPSR1 | |
| Benzene SCHEMBL27988126 | 0.81 | MEN1 (1.00) | KMT2AMEN1MAPTLMNANPSR1 | |
| SCHEMBL935186 | 0.81 | MEN1 (1.00) | KMT2AMEN1MAPTLMNANPSR1 | |
| SCHEMBL1068265 | 0.81 | MEN1 (0.85) | KMT2AMEN1MAPTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575940-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2316831-A1 | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-7767669-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-7767669-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-7767669-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | CHIRON CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | CHIRON CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | CHIRON CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | PI4KB, PI4KA, PDPK1 | KMT2A 2949/4885MEN1 1528/4885MAPT 1941/4885 |
| US-20090060912-A1 | SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KB, AKT3, PI4KA | KMT2A 2719/4885MEN1 1863/4885MAPT 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.